155 related articles for article (PubMed ID: 6764473)
1. Effects of magnesium hydroxide in renal stone disease.
Johansson G; Backman U; Danielson BG; Fellström B; Ljunghall S; Wikström B
J Am Coll Nutr; 1982; 1(2):179-85. PubMed ID: 6764473
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and clinical effects of the prophylactic treatment of renal calcium stones with magnesium hydroxide.
Johansson G; Backman U; Danielson BG; Fellström B; Ljunghall S; Wikström B
J Urol; 1980 Dec; 124(6):770-4. PubMed ID: 7441826
[TBL] [Abstract][Full Text] [Related]
3. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
[TBL] [Abstract][Full Text] [Related]
4. Citrate in urine and serum and associated variables in subgroups of urolithiasis. Results from an outpatient stone clinic.
Schwille PO; Scholz D; Schwille K; Leutschaft R; Goldberg I; Sigel A
Nephron; 1982; 31(3):194-202. PubMed ID: 7121665
[TBL] [Abstract][Full Text] [Related]
5. Magnesium metabolism in renal stone formers. Effects of therapy with magnesium hydroxide.
Johansson G; Backman U; Danielson BG; Fellström B; Ljunghall S; Wikström B
Scand J Urol Nephrol Suppl; 1980; 53():125-34. PubMed ID: 6937988
[No Abstract] [Full Text] [Related]
6. [Effect of verapamil on urinary calcium and oxalate excretion in renal stone formers].
Iguchi M; Ikegami M; Kiwamoto H; Umekawa T; Ishikawa Y; Kohri K; Kurita T
Hinyokika Kiyo; 1993 May; 39(5):425-31. PubMed ID: 8322624
[TBL] [Abstract][Full Text] [Related]
7. Urinary citrate and renal stone disease: the preventive role of alkali citrate treatment.
Caudarella R; Vescini F
Arch Ital Urol Androl; 2009 Sep; 81(3):182-7. PubMed ID: 19911682
[TBL] [Abstract][Full Text] [Related]
8. Magnesium therapy for nephrolithiasis.
Massey L
Magnes Res; 2005 Jun; 18(2):123-6. PubMed ID: 16100850
[TBL] [Abstract][Full Text] [Related]
9. Metabolic effects of bendroflumethiazide in patients with recurrent calcium oxalate stone disease.
Ahlstrand C; Tiselius HG
J Urol; 1981 Nov; 126(5):635-9. PubMed ID: 7299925
[TBL] [Abstract][Full Text] [Related]
10. The effects of potassium and magnesium supplementations on urinary risk factors of renal stone patients.
Jaipakdee S; Prasongwatana V; Premgamone A; Reungjui S; Tosukhowong P; Tungsanga K; Suwantrai S; Noppawinyoowong C; Maskasame S; Sriboonlue P
J Med Assoc Thai; 2004 Mar; 87(3):255-63. PubMed ID: 15117041
[TBL] [Abstract][Full Text] [Related]
11. Urinary excretion of citrate, glycosaminoglycans, magnesium and zinc in relation to age and sex in normal subjects and in patients who form calcium stones.
Trinchieri A; Mandressi A; Luongo P; Rovera F; Longo G
Scand J Urol Nephrol; 1992; 26(4):379-86. PubMed ID: 1292077
[TBL] [Abstract][Full Text] [Related]
12. [Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi].
Hess B
Ther Umsch; 2003 Feb; 60(2):79-87. PubMed ID: 12649986
[TBL] [Abstract][Full Text] [Related]
13. [Effect of cocoa on excretion of oxalate, citrate, magnesium and calcium in the urine of children].
Lagemann M; Anders D; Graef V; Bödeker RH
Monatsschr Kinderheilkd; 1985 Oct; 133(10):754-9. PubMed ID: 4069117
[TBL] [Abstract][Full Text] [Related]
14. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest.
Zerwekh JE; Odvina CV; Wuermser LA; Pak CY
J Urol; 2007 Jun; 177(6):2179-84. PubMed ID: 17509313
[TBL] [Abstract][Full Text] [Related]
15. [Magnesium hydroxide in idiopathic calcium nephrolithiasis].
Vagelli G; Calabrese G; Pratesi G; Mazzotta A; Gonella M
Minerva Urol Nefrol; 1998 Mar; 50(1):113-4. PubMed ID: 9578670
[TBL] [Abstract][Full Text] [Related]
16. Magnesium metabolism in renal stone disease.
Johansson G; Backman U; Danielson BG; Ljunghall S; Wikström B
Invest Urol; 1980 Sep; 18(2):93-6. PubMed ID: 7410037
[TBL] [Abstract][Full Text] [Related]
17. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy.
Pak CY; Sakhaee K; Fuller CJ
Trans Assoc Am Physicians; 1983; 96():294-305. PubMed ID: 6679957
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with long-term bendroflumethiazide treatment in calcium oxalate stone formers.
Ahlstrand C; Tiselius HG; Larsson L; Hellgren E
Br J Urol; 1984 Jun; 56(3):255-62. PubMed ID: 6399984
[TBL] [Abstract][Full Text] [Related]
19. How are urine composition and stone disease affected by therapeutic measures at an outpatient stone clinic?
Tiselius HG; Sandvall K
Eur Urol; 1990; 17(3):206-12. PubMed ID: 2351189
[TBL] [Abstract][Full Text] [Related]
20. Chemical factors important to calcium nephrolithiasis: evidence for impaired hydroxycarboxylic acid absorption causing hyperoxaluria.
Cowley DM; McWhinney BC; Brown JM; Chalmers AH
Clin Chem; 1987 Feb; 33(2 Pt 1):243-7. PubMed ID: 3802507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
